These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 576228)

  • 1. Transient recurrence of hyperthyroidism after delivery in Graves' disease.
    Amino N; Miyai K; Yamamoto T; Kuro R; Tanaka F
    J Clin Endocrinol Metab; 1977 Jan; 44(1):130-6. PubMed ID: 576228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postpartum recurrence of hyperthyroidism and changes of thyroid-stimulating immunoglobulins in Graves' disease.
    Yabu Y; Amino N; Mori H; Miyai K; Tanizawa O; Takai SI; Kumahara Y; Matsuzuka F; Kuma K
    J Clin Endocrinol Metab; 1980 Dec; 51(6):1454-8. PubMed ID: 6108332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum ratio of triiodothyronine to thyroxine, and thyroxine-binding globulin and calcitonin concentrations in Graves' disease and destruction-induced thyrotoxicosis.
    Amino N; Yabu Y; Miki T; Morimoto S; Kumahara Y; Mori H; Iwatani Y; Nishi K; Nakatani K; Miyai K
    J Clin Endocrinol Metab; 1981 Jul; 53(1):113-6. PubMed ID: 6165731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
    Murakami M; Koizumi Y; Aizawa T; Yamada T; Takahashi Y; Watanabe T; Kamoi K
    J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of thyrotropin-releasing hormone on serum thyroid hormones: a study in the patients with untreated and treated Graves' disease and subacute thyroiditis.
    Sato A; Yamada T; Aizawa T; Ichikawa K; Komiya I; Takasu N; Takemura Y
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2173-7. PubMed ID: 7608274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of administration of thyroxine on the risk of postpartum recurrence of hyperthyroid Graves' disease.
    Hashizume K; Ichikawa K; Nishii Y; Kobayashi M; Sakurai A; Miyamoto T; Suzuki S; Takeda T
    J Clin Endocrinol Metab; 1992 Jul; 75(1):6-10. PubMed ID: 1642700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced thyroid iodine metabolism in patients with triiodothyronine-predominant Graves' disease.
    Takamatsu J; Hosoya T; Naito N; Yoshimura H; Kohno Y; Tarutani O; Kuma K; Sakane S; Takeda K; Mozai T
    J Clin Endocrinol Metab; 1988 Jan; 66(1):147-52. PubMed ID: 3335601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.
    Romaldini JH; Bromberg N; Werner RS; Tanaka LM; Rodrigues HF; Werner MC; Farah CS; Reis LC
    J Clin Endocrinol Metab; 1983 Sep; 57(3):563-70. PubMed ID: 6192139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aggravation of thyrotoxicosis in early pregnancy and after delivery in Graves' disease.
    Amino N; Tanizawa O; Mori H; Iwatani Y; Yamada T; Kurachi K; Kumahara Y; Miyai K
    J Clin Endocrinol Metab; 1982 Jul; 55(1):108-12. PubMed ID: 6896207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serial changes in thyroid-stimulating antibody and thyrotropin binding inhibitor immunoglobulin at the time of postpartum occurrence of thyrotoxicosis in Graves' disease.
    Tamaki H; Amino N; Aozasa M; Mori M; Tanizawa O; Miyai K
    J Clin Endocrinol Metab; 1987 Aug; 65(2):324-30. PubMed ID: 2885336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Fluctuations in the titers of anti-thyroid hormone and anti-thyroglobulin antibodies in 4 cases of Graves' disease during long-term treatment period].
    Komaki T; Sakata S; Nakamura S; Matsuda M; Kojima N; Takuno H; Miura K
    Nihon Naibunpi Gakkai Zasshi; 1989 Jul; 65(7):627-39. PubMed ID: 2583311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease.
    Chen JJ; Ladenson PW
    J Clin Endocrinol Metab; 1986 Jul; 63(1):102-6. PubMed ID: 2423547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity to lithium in treated Graves' disease: effects on serum T4, T3 and reverse T3.
    Burman KD; Dimond RC; Earll JM; Wright FD; Wartofsky L
    J Clin Endocrinol Metab; 1976 Sep; 43(3):606-13. PubMed ID: 989049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
    Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T
    N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug.
    McIver B; Rae P; Beckett G; Wilkinson E; Gold A; Toft A
    N Engl J Med; 1996 Jan; 334(4):220-4. PubMed ID: 8531998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroxine and 3,5,3'-triiodothyronine content of thyroglobulin in thyroid needle aspirates in hyperthyroidism and hypothyroidism.
    Laurberg P
    J Clin Endocrinol Metab; 1987 May; 64(5):969-74. PubMed ID: 3558731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroidal triiodothyronine and thyroxine in Graves' disease: correlation with presurgical treatment, thyroid status, and iodine content.
    Larsen PR
    J Clin Endocrinol Metab; 1975 Dec; 41(06):1098-104. PubMed ID: 54364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum triiodothyronine to thyroxine ratio: a newly recognized predictor of the outcome of hyperthyroidism due to Graves' disease.
    Takamatsu J; Kuma K; Mozai T
    J Clin Endocrinol Metab; 1986 May; 62(5):980-3. PubMed ID: 3754263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mechanism of spontaneous hypothyroidism in patients with Graves' disease after antithyroid drug treatment.
    Tamai H; Hirota Y; Kasagi K; Matsubayashi S; Kuma K; Iida Y; Konishi J; Okimura MC; Walter RM; Kumagai LF
    J Clin Endocrinol Metab; 1987 Apr; 64(4):718-22. PubMed ID: 2434520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reappraisal of the 3,5,3'-triiodothyronine-suppression test in the prediction of long term outcome of antithyroid drug therapy in patients with hyperthyroid Graves' disease.
    Yamada T; Koizumi Y; Sato A; Hashizume K; Aizawa T; Takasu N; Nagata H
    J Clin Endocrinol Metab; 1984 Apr; 58(4):676-80. PubMed ID: 6421866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.